Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinusitis Hevert SL in acute uncomplicated rhinosinusitis
NCT02296814Phase 4Completed
- Sponsor
- Hevert-Arzneimittel
- Start
- Nov 2014
- Primary completion
- Apr 2015
- Modality
- Homeopathic Remedy, Botanical Extract
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute rhinosinusitis (ARS) comparing Sinusitis Hevert SL with Placebo (2 arms). Primary endpoints: Rate of responders at 2 weeks and Rate of remissions at 2 weeks. Started Nov 2014; status: completed.
02
Drugs
Sinusitis Hevert SL
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on NCT02296814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296814.